PHILADELPHIA, July 28, 2015 /PRNewswire/ -- Clincierge™, the leading provider of specialized services and personalized support designed to overcome barriers to patient participation in clinical studies, today announced the expansion of its innovative "patient concierge" service into Cyprus. This event marks the 30th country where the company's high-touch, one-on-one services for patients and families are available to aid companies conducting clinical trials increase trial enrollment and improve patient retention, thus helping to ensure that costly studies complete on time and on budget.
"Since its inception two years ago, Clincierge has supported multiple studies internationally for pharmaceutical companies and contract research organizations with great success and overwhelming positive feedback from patients, research site personnel and sponsors," said Scott Gray, Clincierge chief executive officer. "By offering patients and their families personalized services in their own language from their own in-country coordinator, and providing patients ease-of-access to research sites, studies using Clincierge have seen increased enrollment and have maintained drop-out rates of less than 5%. Moreover, the cost of incorporating Clincierge services has averaged less than 1% to overall clinical trial costs."
Offering personalized support to trial participants and their families alleviates anxieties about trial-related travel, expenses and other issues that can get in the way of patients enrolling and staying in a clinical study. "The ultimate goal of Clincierge is to aid drug developers in reducing overall clinical testing time and cost by making clinical trials more patient-centric, thus helping ensure that new treatments get to the market and to patients who need them as swiftly as possible," Mr. Gray concluded.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.